Cookson Peirce & Co. Inc. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 106.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,023 shares of the company’s stock after buying an additional 6,193 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Neurocrine Biosciences were worth $1,292,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the business. Pictet Asset Management Ltd. increased its stake in Neurocrine Biosciences by 9.6% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,041,000 shares of the company’s stock valued at $93,805,000 after buying an additional 91,310 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $64,739,000. GW&K Investment Management LLC increased its stake in shares of Neurocrine Biosciences by 26.2% during the 3rd quarter. GW&K Investment Management LLC now owns 297,228 shares of the company’s stock worth $26,783,000 after purchasing an additional 61,645 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Neurocrine Biosciences by 15.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 204,000 shares of the company’s stock worth $18,382,000 after purchasing an additional 27,000 shares during the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Neurocrine Biosciences by 330.3% during the 3rd quarter. Squarepoint Ops LLC now owns 165,704 shares of the company’s stock worth $14,932,000 after purchasing an additional 127,195 shares during the last quarter. Hedge funds and other institutional investors own 96.33% of the company’s stock.
Several brokerages have recently issued reports on NBIX. Zacks Investment Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $124.00 price target for the company in a research note on Wednesday, January 8th. Piper Jaffray Companies restated an “overweight” rating and set a $153.00 price target (up previously from $116.00) on shares of Neurocrine Biosciences in a research note on Thursday, December 12th. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, January 23rd. BidaskClub lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. Finally, Royal Bank of Canada restated a “buy” rating and set a $125.00 price target on shares of Neurocrine Biosciences in a research note on Monday, January 20th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $116.92.
In related news, Director Gary A. Lyons sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $100.22, for a total value of $501,100.00. Following the completion of the transaction, the director now directly owns 230,697 shares of the company’s stock, valued at approximately $23,120,453.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dimitri E. Grigoriadis sold 10,188 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $100.34, for a total transaction of $1,022,263.92. Following the completion of the transaction, the insider now directly owns 118,596 shares of the company’s stock, valued at $11,899,922.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,465 shares of company stock valued at $4,237,168. 4.30% of the stock is owned by insiders.
NBIX opened at $98.65 on Tuesday. The company has a 50 day moving average of $107.92 and a 200 day moving average of $100.95. The company has a market cap of $9.03 billion, a PE ratio of 580.29, a price-to-earnings-growth ratio of 1.08 and a beta of 1.21. Neurocrine Biosciences, Inc. has a 12 month low of $71.85 and a 12 month high of $119.65. The company has a current ratio of 7.08, a quick ratio of 6.99 and a debt-to-equity ratio of 0.83.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The business had revenue of $222.09 million during the quarter, compared to the consensus estimate of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The firm’s quarterly revenue was up 46.3% on a year-over-year basis. During the same period last year, the business posted $0.52 earnings per share. Research analysts forecast that Neurocrine Biosciences, Inc. will post 0.88 earnings per share for the current fiscal year.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.